Latest Strategy Changes News

KGL Resources has paused drilling to deploy advanced 3D geophysical modelling, revealing significant deep mineral anomalies at its Jervois Project. The company is advancing construction readiness and securing funding amid strong copper, silver, and gold markets.

IODM Limited reported a robust 37% increase in cash receipts for Q4 FY25, driven by strong UK education sector growth and new international revenue share agreements.

Resonance Health reports a solid quarter with key clinical trial milestones, expansion of trial sites, and multi-year Software-as-a-Medical Device contracts, underpinning a positive cashflow outlook.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

Burgundy Diamond Mines has updated its Ekati Diamond Mine Life of Mine plan through 2040, extending Misery underground operations and advancing the Fox Underground project with strong economic prospects.

FirstWave Cloud Technology reports a slight revenue decline in Q4 FY25, offsets challenges with strategic restructuring and a new AWS marketplace partnership.

Hydrix Limited reports steady June quarter revenues with a 10% rise from the prior quarter, supported by new contract wins and a robust $40 million project pipeline.

PhosCo Ltd reports significant progress at its Gasaat Phosphate Project in Tunisia, unveiling promising drilling results and securing potential strategic investment from the EBRD to fund its next development phase.

HALO Technologies reports $3.54 million in Q2 revenue with rising subscription income, progressing UK expansion pending FCA approval, and a $6.75 million capital raise nearing completion.

Beacon Minerals reported a 20% increase in gold production to 7,365 ounces in the June 2025 quarter, alongside significant drilling progress at the Iguana deposit and a strategic share consolidation and buy-back program.

Galilee Energy reported operational cost reductions and a $2.8 million cash balance following a partial capital raise, while progressing a farm-out process for its Denison Trough permit.

Imugene Limited reports strong clinical progress with its off-the-shelf CAR T therapy azer-cel achieving a 75% overall response rate in Phase 1b trials, alongside new patents and leadership appointments. The company also secured $22.5 million in fresh funding to advance pivotal trials.